Domestic Pharma Market Grows 8.8% in FY26; Torrent, Cipla Lead ₹2.46 Lakh Crore Sector
India’s domestic pharmaceutical market grew 8.8% in FY26 to ₹2.46 lakh crore, with Torrent and Cipla emerging as top performers amid steady demand.
Akanksha jain 
Published on: April 2026
India’s domestic pharmaceutical market recorded an 8.8% growth in FY26, reaching a value of ₹2.46 lakh crore, driven by strong demand across major therapy segments. Companies emerged as leading performers in the competitive landscape.
The India pharma market growth FY26 highlights resilience in domestic demand despite pricing pressures and regulatory challenges affecting the sector.
Growth Driven by Key Therapy Segments
The market expansion was supported by strong performance in key therapeutic areas, including:
- Cardiac care
- Anti-diabetes treatments
- Respiratory therapies
- Gastrointestinal medicines
Chronic therapies contributed significantly due to rising lifestyle diseases such as hypertension and diabetes, while acute therapies maintained stable demand.
Torrent and Cipla Lead Market Performance
reported strong growth during FY26, driven by their focus on chronic therapy portfolios and market expansion strategies.
Their performance reflects the importance of product mix, brand strength, and execution in driving growth within the domestic pharmaceutical market.
Pricing and Cost Pressures Persist
Despite growth, the sector continues to face margin pressures due to rising input costs and regulatory price caps on essential medicines.
Companies are adopting strategies such as the following:
- Supply chain optimisation
- Cost efficiency improvements
- Focus on high-margin products
Importance of Domestic Market Stability
The domestic market provides stability to Indian pharmaceutical companies, complementing export-driven revenues and ensuring consistent growth.
Growth is supported by:
- Improved healthcare access
- Rising disease awareness
- Government healthcare initiatives
Outlook for the Indian Pharma Sector
The strong FY26 performance indicates continued growth potential, although companies must navigate regulatory, pricing, and demand-related challenges.
The India pharma market growth FY26 reinforces the sector’s role as a key pillar of the healthcare ecosystem, supporting access to medicines and public health outcomes.
